FORMULATION AND DEVELOPMENT OF EFAVIRENZ TABLETS BY PAPER TECHNIQUE USING CO-SOLVENCY METHOD

  • CH. DHANA SUBRAHMANYESWARI Department of Pharmaceutics, School Of Pharmaceutical Science and Technology, JNTU, Kakinada–533001, Andhra Pradesh, India
  • Y. PRASANTH Department of Pharmaceutics, School Of Pharmaceutical Science and Technology, JNTU, Kakinada–533001, Andhra Pradesh, India
  • SAMEEDA RUBEEN Department of Pharmaceutics, School Of Pharmaceutical Science and Technology, JNTU, Kakinada–533001, Andhra Pradesh, India

Abstract

Objective: The present study is to formulate and development of efavirenz tablets by paper technique using the co-solvency method, the drug is antiviral drug used for the treatment of HIV.


Methods: In this 7 formulation (F1-F7) were prepared by using different tissue papers like kitchen roll paper, hand kercheif paper, facial tissue paper, with different weights. The prepared tablets were evaluated for hardness, friability, thickness, content uniformity, disintegration time and in vitro dissolution study.


Results: Among all the formulations, F2 (kicthen roll paper with weight 250 mg) was consired to be the best formulation, which release up to 98.02% drug in 3 h. The results of stability studies of formulation F2 after a period of 2 mo indicated that the formulation was stable.


Conclusion: It was concluted that a paper tablet of efavirenz shows better results and it does not contain any excipient and increase the dissolution rate.

Keywords: Efavirenz, Tissue paper, Disintegration, In vitro dissolution

References

1. Ketan T Savjani, Anuradha K Gajjar, Jignasa K Savjani. Drug solubility: importance and enhancement techniques. ISRN Pharm 2012. Doi:10.5402/2012/195727.
2. Poonam Kesarwani, Sameer Rastogi, Vijay Bhalla, Vandana Arora. Solubility enhancement of poorly water-soluble drugs: a review. Int J Pharm Sci Res 2014;5:3123-7.
3. Sikarra Deepshikha, Shukla Vaibhav, Kharia Ankit Anand, Chatterjee DP. techniques for solubility enhancement of poorly soluble drugs: an overview, review article. J Med Pharm Allied Sci 2012;1:18-38.
4. Parve B, Shinde P, Rawat S, Rathod S. Waghmode G. Solubility enhancement techniques: a review. World J Pharm Pharm Sci 2014;3:400-22.
5. Adarsh Kesharwani, Anuradha Kesharwani, Md Amman Maqbool. Solubilization enhancement techniques: an overview. Pharm Chem J 2017;4:121-30.
6. Drug bank open data drug and drug target database. Available from: https://www.drugbank.ca/drugs/DB00625 [Last accessed on 02 Jul 2019].
7. Rowe RC, Sheskey, Owen SC. editor. Handbook of pharmaceutical excipients 5thed. Uk: PhP Pharmaceutical Press; 2006.
8. Suhas B Gurav, Anant N Deshpande, Jadge Dhanraj, Sandeep D Walsangikar. Spectrophotometric estimation of efavirenz in the formulation and biological fluid. Asian J Biochem Pharm Res 2011;1:402-6.
9. Florian Stumpf, Cornelia M Keck. Tablets made from paper. Available from: https://doi.org/10.1016/j.ijpharm.2018.05.071 [Last accessed on 02 Jul 2019]
10. Leon Lachman, Herbert A Lieberman, Jopesh L Kaing. The theory and practice of industrial pharmacy. 3rd edition; 1987. p. 293, 294, 296, 311-9.
11. Michele Danish, Mary Kathryn Kottke. In: Gilbert Banker, Cristopher T. Rhodes Eds. Modern pharmaceutics. 3rd edition. Marcel Deccker, Inc New–York; 1996.
12. Arendt G, de Nocker D, Von Giesen HJ, Nolting T. Expert opin. Drug Saf 2007;6:147.
13. Gallego L, Barreiro P, del Rio R, Gonzalez De Requena D, Rodriguez-Albarino A, Gonzalez-Lahoz J, Soriano V. Analyzing sleep abnormalities in HIV-infected patients treated with efavirenz. Clin Infect Dis 2004;38:430.
14. Kuritzkes DR, Ribaudo HJ, Squires KE, Koletar SL, Santana J, Riddler SA, et al. Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s. J Infect Dis 2007;195:1169-76.
Statistics
46 Views | 37 Downloads
Citatons
How to Cite
SUBRAHMANYESWARI, C. D., Y. PRASANTH, and S. RUBEEN. “FORMULATION AND DEVELOPMENT OF EFAVIRENZ TABLETS BY PAPER TECHNIQUE USING CO-SOLVENCY METHOD”. International Journal of Current Pharmaceutical Research, Vol. 11, no. 6, Nov. 2019, pp. 87-92, doi:10.22159/ijcpr.2019v11i6.36349.
Section
Original Article(s)